| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Over the last 12 months, insiders at Anavex Life Sciences Corp. have bought $0 and sold $0 worth of Anavex Life Sciences Corp. stock.
On average, over the past 5 years, insiders at Anavex Life Sciences Corp. have bought $21,925 and sold $3.48M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,835 shares for transaction amount of $10,319 was made by Donhauser Peter D.O. (director) on 2024‑06‑14.
| 2024-06-14 | Donhauser Peter D.O. | director | 2,835 0.0033% | $3.64 | $10,319 | +114.06% | ||
| 2024-05-15 | Thomas Steffen | director | 5,000 0.0059% | $4.52 | $22,600 | +72.49% | ||
| 2024-03-28 | Sale | MISSLING CHRISTOPHER U | President and CEO | 73,380 0.0911% | $5.11 | $374,972 | +19.55% | |
| 2023-06-28 | Sale | MISSLING CHRISTOPHER U | President and CEO | 268,000 0.3424% | $7.98 | $2.14M | -24.69% | |
| 2022-05-25 | Sale | Skarpelos Athanasios | 50,000 0.0643% | $9.06 | $453,000 | +8.46% | ||
| 2021-06-29 | Sale | MISSLING CHRISTOPHER U | President and CEO | 51,620 0.0805% | $26.00 | $1.34M | -28.27% | |
| 2021-06-29 | Sale | Boenisch Sandra | PFO and Treasurer | 166,696 0.2651% | $26.53 | $4.42M | -28.27% | |
| 2021-05-21 | Sale | FAVUS ELLIOT | director | 145,000 0.2057% | $11.70 | $1.7M | +49.44% | |
| 2021-05-17 | Donhauser Peter D.O. | director | 1,000 0.0014% | $10.93 | $10,930 | +54.43% | ||
| 2021-02-24 | Sale | FAVUS ELLIOT | director | 145,500 0.2172% | $12.66 | $1.84M | +40.94% | |
| 2021-02-19 | Donhauser Peter D.O. | director | 1,165 0.0017% | $12.67 | $14,760 | +38.92% | ||
| 2018-03-07 | MISSLING CHRISTOPHER U | President and CEO | 1,360 0.0031% | $2.92 | $3,971 | -13.15% | ||
| 2018-03-06 | MISSLING CHRISTOPHER U | President and CEO | 1,450 0.003% | $2.73 | $3,959 | -14.33% | ||
| 2018-03-05 | MISSLING CHRISTOPHER U | President and CEO | 1,500 0.0034% | $2.63 | $3,945 | -4.20% | ||
| 2018-03-02 | MISSLING CHRISTOPHER U | Director, President & CEO | 1,650 0.0034% | $2.41 | $3,977 | -3.85% | ||
| 2017-10-25 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.39 | $1,646 | -36.81% | ||
| 2017-10-24 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.92 | $1,845 | -41.40% | ||
| 2017-10-19 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0008% | $4.49 | $1,684 | -40.47% | ||
| 2017-10-17 | MISSLING CHRISTOPHER U | President and CEO | 375 0.0009% | $4.27 | $1,601 | -34.35% | ||
| 2017-10-13 | MISSLING CHRISTOPHER U | President and CEO | 750 0.0017% | $4.22 | $3,165 | -34.58% |
| Skarpelos Athanasios | 1306458 1.4098% | $4.76M | 1 | 6 | ||
| MISSLING CHRISTOPHER U | President and CEO | 1250210 1.3491% | $4.55M | 39 | 3 | +42.64% |
| Lalach Harvey | President COO Secretary | 550000 0.5935% | $2M | 0 | 8 | |
| Boenisch Sandra | PFO and Treasurer | 22963 0.0248% | $83,585.32 | 0 | 1 | |
| Thomas Steffen | director | 5000 0.0054% | $18,200.00 | 1 | 0 | +72.49% |
| Donhauser Peter D.O. | director | 5000 0.0054% | $18,200.00 | 3 | 0 | +69.14% |
| Wu Pei Ru | COO | 0 0% | $0 | 0 | 1 | |
| Wu Yang | President & CEO | 0 0% | $0 | 0 | 1 | |
| FAVUS ELLIOT | director | 0 0% | $0 | 0 | 2 |
$27,004,904 | 102 | 5.82% | $331.11M | |
$17,468,215 | 46 | 18.85% | $369.1M | |
Anavex Life Sciences Corp. (AVXL) | $130,095 | 43 | 45.19% | $337.33M |
$54,828,550 | 26 | -13.88% | $376.37M | |
$3,668,031 | 23 | 2.05% | $313.77M | |
$22,365,077 | 19 | -27.47% | $349.72M | |
$1,447,973 | 17 | 13.95% | $309.83M | |
$135,812,721 | 14 | 17.52% | $329.12M | |
$10,399,379 | 13 | 13.60% | $325.27M | |
$112,952,085 | 11 | -19.19% | $369.16M | |
$2,687,954 | 9 | 15.20% | $355.67M | |
$6,847,110 | 9 | 5.96% | $341.57M | |
$119,804,612 | 8 | -17.22% | $360.71M | |
$13,043,783 | 8 | 732.82% | $331.15M | |
$1,346,998 | 7 | 25.06% | $369.56M | |
$164,999,952 | 5 | -44.44% | $310.19M | |
$12,035,408 | 5 | -37.54% | $376.23M | |
$15,551,156 | 3 | 98.82% | $319.19M | |
$4,888,000 | 3 | -20.50% | $310.52M |
| Increased Positions | 89 | +41.4% | 8M | +23.27% |
| Decreased Positions | 86 | -40% | 2M | -7.27% |
| New Positions | 28 | New | 2M | New |
| Sold Out Positions | 31 | Sold Out | 944,254 | Sold Out |
| Total Postitions | 218 | +1.4% | 38M | +16% |
| Blackrock, Inc. | $26,453.00 | 8.08% | 7.19M | +186,507 | +2.66% | 2025-09-30 |
| Vanguard Group Inc | $18,785.00 | 5.74% | 5.1M | -2,357 | -0.05% | 2025-09-30 |
| State Street Corp | $12,097.00 | 3.69% | 3.29M | +338,310 | +11.47% | 2025-09-30 |
| Geode Capital Management, Llc | $7,461.00 | 2.28% | 2.03M | +7,532 | +0.37% | 2025-09-30 |
| Two Sigma Investments, Lp | $3,816.00 | 1.17% | 1.04M | +63,685 | +6.54% | 2025-09-30 |
| Nwam Llc | $3,217.00 | 0.98% | 874,283 | -150,196 | -14.66% | 2025-09-30 |
| Northern Trust Corp | $2,845.00 | 0.87% | 773,012 | -4,153 | -0.53% | 2025-09-30 |
| Two Sigma Advisers, Lp | $2,791.00 | 0.85% | 758,500 | -64,900 | -7.88% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $2,640.00 | 0.81% | 717,378 | +7,762 | +1.09% | 2025-09-30 |
| Susquehanna International Group, Llp | $2,222.00 | 0.68% | 603,818 | -2,849 | -0.47% | 2025-09-30 |